Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

BACKGROUND: Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long‐term efficacy and safety of apremilast in biologic‐naive patients with moderate to severe plaque psoriasis and safety of switching from...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873268/
https://www.ncbi.nlm.nih.gov/pubmed/29220542
http://dx.doi.org/10.1111/jdv.14738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873268/
https://www.ncbi.nlm.nih.gov/pubmed/29220542
http://dx.doi.org/10.1111/jdv.14738

Ejemplares similares